Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R



TSX:CXR.R - Post by User

Comment by adamchesson Nov 02, 2015 11:29am
167 Views
Post# 24250208

RE:irrational exuberance

RE:irrational exuberancecarlos: It takes less than 5 minutes to determine that Concordia's business model is excellent in the short and long-term and their cashflow easily covers their interest and debt requirements for all time periods. With excess cashflows they can either pay off debt quickly and/or make further investments in product to improve the business even further. A no-brainer at these prices.


Carlos66 wrote: let's not get too far ahead of ourselves regarding CXR's future.

A guest from CIBC had a list of companies whose business model is growth by acquisiton ranked by a different set of metrics & he mentioned that going forward there will be more scrutiny of acquisitions etc.. That will slow down growth  for all regardless of the sector they are in with only those that are not over-leveraged & in debt.

That being said it seems that the Citron analyst Left has backtracked from his inflammatory statement on Friday that the end of the world is coming to VRX probably according to a side comment from Amber Kanwar, his lawyers told him to dial the rhetoric back a bit. Now he says that this will be his last comment on VRX & that he will be moving on to other targets. I wonder which other Cdn. companies he will focus on next.

Hopefully with more & more companies (banks, MMs) coming out with new & higher price targets now that the rush to judgment/rhetoric is waning & a return to sound/sane economic/financial investment advice.

The company should continue to expound the difference between VRX & CXR's business model & come out with frequent NR about what & with whom they are doing business, because as I said above more scrutiny by all those who give financial advice including gov't regulators/PBMs who will scrutinize prices they have to pay.

An unintended consequence...IMO... might be orphan drug status pricing. Not related

I suspect CXR recovery might be slower than expected not unlike the oil sector earlier expectations of an oil price recovery... lower for longer now.
1st we must get above $60. (maybe by yearend) & then we can talk about $100. & more; so talking about targets above $100. now are more talking your book than anything else.

carlos



<< Previous
Bullboard Posts
Next >>